Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

  • Showing results for a modified search because your search retrieved no results.
1.

A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17.

Giagulli C, D'Ursi P, He W, Zorzan S, Caccuri F, Varney K, Orro A, Marsico S, Otjacques B, Laudanna C, Milanesi L, Dolcetti R, Fiorentini S, Lu W, Caruso A.

Sci Rep. 2017 Jul 26;7(1):6555. doi: 10.1038/s41598-017-06848-y.

2.

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity.

Simpson DA, Lemonie N, Morgan DS, Gaddameedhi S, Kaufmann WK.

Cancers (Basel). 2015 Jun 17;7(2):1072-90. doi: 10.3390/cancers7020825.

3.

Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway.

Liu Y, Zhang Y, Jia K, Dong Y, Ma W.

Exp Ther Med. 2015 Apr;9(4):1401-1406. Epub 2015 Jan 27.

4.

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.

Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.

5.

Wild-type RAS: keeping mutant RAS in CHK.

Anastassiadis T, Brown EJ.

Cancer Cell. 2014 Feb 10;25(2):137-8. doi: 10.1016/j.ccr.2014.01.029.

6.
7.

Akt switches TopBP1 function from checkpoint activation to transcriptional regulation through phosphoserine binding-mediated oligomerization.

Liu K, Graves JD, Scott JD, Li R, Lin WC.

Mol Cell Biol. 2013 Dec;33(23):4685-700. doi: 10.1128/MCB.00373-13. Epub 2013 Sep 30.

8.

CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.

Brunetto E, Ferrara AM, Rampoldi F, Talarico A, Cin ED, Grassini G, Spagnuolo L, Sassi I, Ferro A, Cuorvo LV, Barbareschi M, Piccinin S, Maestro R, Pecciarini L, Doglioni C, Cangi MG.

Neoplasia. 2013 Jun;15(6):579-90.

9.

Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.

Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK.

Ann N Y Acad Sci. 2012 Oct;1271:58-67. doi: 10.1111/j.1749-6632.2012.06734.x. Review. Erratum in: Ann N Y Acad Sci. 2013 Sep;1299:100.

10.

Akt: a double-edged sword in cell proliferation and genome stability.

Xu N, Lao Y, Zhang Y, Gillespie DA.

J Oncol. 2012;2012:951724. doi: 10.1155/2012/951724. Epub 2012 Mar 15.

11.

P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation.

Li P, Goto H, Kasahara K, Matsuyama M, Wang Z, Yatabe Y, Kiyono T, Inagaki M.

Mol Biol Cell. 2012 Apr;23(8):1582-92. doi: 10.1091/mbc.E11-10-0883. Epub 2012 Feb 22.

12.
13.

Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci.

Tonic I, Yu WN, Park Y, Chen CC, Hay N.

J Biol Chem. 2010 Jul 30;285(31):23790-8. doi: 10.1074/jbc.M110.104372. Epub 2010 May 21.

14.

An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling.

Schreiber TB, Mäusbacher N, Kéri G, Cox J, Daub H.

Mol Cell Proteomics. 2010 Jun;9(6):1047-62. doi: 10.1074/mcp.M900486-MCP200. Epub 2010 Jan 12.

15.

Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair.

Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER.

Mol Biol Cell. 2009 Jul;20(14):3374-89. doi: 10.1091/mbc.E09-01-0085. Epub 2009 May 28.

16.

Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Lin JE, Li P, Pitari GM, Schulz S, Waldman SA.

Future Oncol. 2009 May;5(4):509-22. doi: 10.2217/fon.09.14. Review.

17.

Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Madson JG, Lynch DT, Svoboda J, Ophardt R, Yanagida J, Putta SK, Bowles A, Trempus CS, Tennant RW, Hansen LA.

Am J Pathol. 2009 Jun;174(6):2357-66. doi: 10.2353/ajpath.2009.080638. Epub 2009 Apr 30.

18.

Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling.

Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, Reddy SP.

Oncogene. 2008 Oct 2;27(44):5821-32. doi: 10.1038/onc.2008.188. Epub 2008 Jun 9.

19.

AKT/PKB signaling: navigating downstream.

Manning BD, Cantley LC.

Cell. 2007 Jun 29;129(7):1261-74. Review.

20.

Specific role of Chk1 phosphorylations in cell survival and checkpoint activation.

Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M.

Mol Cell Biol. 2007 Apr;27(7):2572-81. Epub 2007 Jan 22.

Supplemental Content

Support Center